• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl assists the biotechnology company AegirBio in carrying out a multinational acquisition and merger

  • Home
  • Latest news
  • Cases and transactions
  • 2021
  • Lindahl assists the biotechnology company AegirBio in carrying out a multinational acquisition and merger

Lindahl has assisted AegirBio AB (‘AegirBio’) in acquiring Abreos Biosciences Inc. and its wholly-owned French subsidiary Abreos France (jointly ‘Abreos’) and in the merger of AegirBio and LifeAssays AB (plc) (‘LifeAssays’).

The acquisition of Abreos is being transacted by means of a non-cash issue of 1,988,862 AegirBio shares. The merger of AegirBio and LifeAssays is done through an absorption under company law whereby LifeAssays’ shareholders are offered a 0.0616 share in AegirBio for each share they hold in LifeAssays.

Abreos is based in San Diego, California, USA, and focuses on so-called precision medicine. Abreos uses its Veritope Technology platform to produce novel peptide sequences (mimotopes) which immunologically mimic the molecules to which biological medicines are bound. This enables precise drug monitoring of surpluses or deficiencies in a patient’s blood and adjusting the treatment individually. Veritopes can also be quickly and cost-effectively developed for testing immune response to viruses and bacteria, e.g. for specifically measuring antibodies against COVID-19.

ÆgerBio is a Swedish diagnostics company which uses it unique patented technology platform to provide testing for monitoring and optimising the dosage of biological drugs. By merging with LifeAssays and acquiring Abreos, AegirBio has secured a world-leading technology platform for the products that will take AegirBio into the future and pave the way to new expansion opportunities on the world market.

​Lindahl’s securities law team comprised Dennis Westermark, Monica Lagercrantz, Ola Svanberg and Gustav Ahlgren, while M&A expertise was provided by Henrik Nobel and Nicklas Bexelius.

Contact

  • Dennis Westermark

    Stockholm

    [email protected] +46 761 269 102
  • Monica Lagercrantz

    Stockholm

    [email protected] +46 761 269 109
  • Ola Svanberg

    Stockholm

    [email protected] +46 761 269 115
  • Gustav Ahlgren

    Stockholm

    [email protected] +46 734 158 215
  • Henrik Nobel

    Stockholm

    [email protected] +46 708 224 480
Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm [email protected] +46 8 527 70 800
  • Göteborg [email protected] +46 31 799 10 00
  • Malmö [email protected] +46 40 664 66 50
  • Uppsala [email protected] +46 18 16 18 50
  • Örebro [email protected] +46 19 20 89 00
  • Helsingborg [email protected] +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience